Lo.G protects medicines in transit

Published: 27-May-2010

LIVE FROM TOTAL PROCESS & PACKAGING

Plastique, a UK-based plastics thermoforming firm, is offering protective packaging for fragile items such as medicines.

The Lo.G protects products in transit with the help of a patented 360° impact absorbing buffer system, which ensures that contents are centrally cushioned and protected.

Lo.G packs are made from recycled HDPE plastic. As a nesting product, they offer weight, space and energy savings throughout the supply chain, from warehousing to point-of-sale, when compared with EPS block or foam protective packaging.

Plastique of Tunbridge Wells, Kent offers the Lo.G packaging in single piece ‘wrap-round and lock’ boxes or end cap formats to suit a variety of products.

The company also unveiled Paperlite rPET material developed by Flextrus of Sweden, which is an alternative to thermoformed plastic trays.

According to Plastique’s sales and marketing executive, Daryl Thompson, PaperLite can be used for packaging drugs or medical devices. The material, which looks and feels like paper, is based on FibreForm from Billerud and will run on existing form fill and seal lines. It is also FSC certified and has environmental advantages over thermoformed plastic trays.

PaperLite won the Packaging Innovation Award 2009 at the Scanpack exhibition in Gothenburg.

See more

You may also like

Manufacturing

Replacing discontinued OEM degasser modules

Read more
Biotech Fluidics introduces direct replacement OEM degasser modules based on upgraded vacuum technology to support continued fluidic instrument supply without costly redesigns

Trending Articles

  1. FDA approves AstraZeneca's FASENRA for hypereosinophilic syndrome AstraZeneca's FASENRA has received FDA approval for hypereosinophilic syndrome in adults and adolescents aged 12 and above, based on Phase III NATRON trial data showing a 65% reduction in the risk of first HES flare compared to placebo
  2. MHRA approves every-four-week dosing regimen for Chiesi's Elfabrio in stable adult Fabry disease patients The firm has received MHRA approval for an additional 2 mg/kg every-four-week dosing regimen for pegunigalsidase alfa, halving the number of annual infusions required for eligible adult Fabry disease patients from 26 to 13
  3. FDA issues first cGMP warning letter citing AI misuse in pharmaceutical manufacturing A Michigan-based lab has become the subject of the FDA's first dedicated enforcement action on artificial intelligence misuse in drug manufacturing — a landmark event with far-reaching implications for cGMP compliance across the pharmaceutical supply chain
  4. embecta completes £100m acquisition of UK-based Owen Mumford to bolster drug delivery portfolio US diabetes care company embecta has finalised its acquisition of Owen Mumford, gaining access to the Aidaptus next-generation auto-injector platform as it accelerates its transition into a broad-based medical supplies company
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Wearable pumps and subcutaneous delivery: a new frontier in heart failure management Two recent developments are reshaping how drug delivery technology can move treatment out of the clinic and into patients’ everyday lives — with implications for both formulation science and device manufacturing

Upcoming event

Cleanroom Technology Conference UK

20-21 May 2026 | Conference and Exhibition | Birmingham, UK See all

You may also like

Manufacturing

Replacing discontinued OEM degasser modules

Biotech Fluidics introduces direct replacement OEM degasser modules based on upgraded vacuum technology to support continued fluidic instrument supply without costly redesigns
Cell & Gene Therapy

NGI Stockholm becomes first certified service provider for Epigenica's EpiFinder platform

Epigenica has signed an agreement with the National Genomics Infrastructure in Stockholm to offer end-to-end EpiFinder workflows for histone and DNA methylation profiling, establishing the first certified service provider in what the company describes as a growing global partner network
Manufacturing

etherna's mRNA and LNP platforms advance Dropshot Therapeutics' renal disease programme to clinical stage

etherna has announced that partner Dropshot Therapeutics has validated its platforms in preclinical renal disease research and will now progress to IND-enabling studies, with etherna providing GMP manufacturing support ahead of planned Phase I clinical trials in 2027
Manufacturing

CARBOGEN AMCIS introduces SPRINT for early-phase development

A new, phase-appropriate approach designed to accelerate early-phase progression while maintaining scientific rigour
Manufacturing

FUJIFILM Cellular Dynamics opens new iPSC manufacturing facility in US

The new site will serve as the company's headquarters and will increase Fujifilm's capacity for induced pluripotent stem cell development and manufacturing, as demand increases with new approach methods in research
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

From bespoke to scalable: closing the manufacturing gap in advanced therapeutics

Dr Kevin Robinson (KSR) spoke to Cytiva’s Nicolas Pivet (NP), Vice President of Manufacturing and Digital Solutions, to find out how digitalisation and scalable manufacturing platforms are shaping the next phase of advanced therapeutics

Shimadzu launches integrated HPLC/UHPLC systems

These compact, robust instruments feature Analytical Intelligence with auto-diagnostics and auto-recovery, reducing downtime and operator workload
Subscribe now